LUPIN

The Indian pharmaceutical industry has grown tremendously especially post-pandemic. According to the Economic Survey 2020-21, the domestic market is expected to grow 3 times in the upcoming decade and is estimated to reach US$ 65 billion by 2024. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK.

Lupin is one of the largest pharmaceutical company offering a wide range of branded and generic formulated medicines, NSAIDs, biotechnology products, active pharmaceutical ingredients and more. The company have an extensive geographical footprint presence in over 100 countries offering affordable superior quality medicines and 15 manufacturing facilities across India, the US, Mexico and Brazil. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective and Non-Steroidal Anti-Inflammatory Drugs.

Lupin soars 8%, hits over a three-year high on heavy volumes and also plans expansion aiming to enter the Chinese market in the next year.   Lupin has been awarded as India Pharma CSR Programme of The Year Award by the Department of Pharmaceuticals, Govt. Of India.

The Board of Directors has recommended a final dividend of Rs. 6.50 per equity share for the year ended March 2021. Also, as per Q4 FY21 results, Lupin got a 5.05% sequential growth in consolidated profit against the previous quarter and revenue fell by 5.83% against the December quarter. PBT fell by 1.23% QoQ & the gross profit margin fell by 4.88% QoQ. While Earnings per share (EPS) increased by 5.14% and assets grew by 3.99%

The Q4 results of Lupin were conspicuous.